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A high expression level of epidermal growth factor receptor (EGFR)/HER1 has been suggested to lead to a shorter survival time and
resistance to endocrine therapy in patients with breast cancer. To test the hypothesis that inhibition of the EGFR signalling pathway
affects the antitumour effect of endocrine therapy, an EGFR tyrosine kinase inhibitor (EGFR-TKI), gefitinib, and an oestrogen receptor
(ER) antagonist, fulvestrant, were administered to human breast cancer cells. A total of five human breast cancer cell lines were used.
The effects of single or combined treatments with gefitinib and/or fulvestrant on cell growth, cell cycle progression and apoptosis
were analysed. Changes in the expression levels of cyclin-dependent kinase inhibitors, p21 and p27, an antiapoptotic factor, Bcl-2, and
a proapoptotic factor, Bax, were also investigated. All cell lines tested were sensitive to gefitinib (50% growth inhibitory concentration,
10–28.5mM). Breast cancer cell lines with a high expression level of HER1 or HER2 were more sensitive to gefitinib than the others.
Gefitinib induced a significant G1–S blockade in ER-positive KPL-3C cells. Gefitinib induced significant apoptosis in HER1-
overexpressing MDA-MB-231 cells. Gefitinib additively increased the antitumour effect of fulvestrant in all three ER-positive cell lines
in a medium supplemented with 17b-oestradiol. The combined treatment promoted cell cycle retardation in KPL-3C cells, which is
associated with an upregulation of p21 by fulvestrant and gefitinib, respectively. Apoptosis was associated with downregulation of Bcl-
2 by gefitinib in MDA-MB-231 cells. These results suggest an additive interaction between the EGFR-TKI gefitinib and the
antioestrogen fulvestrant in ER-positive breast cancer cells.
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Epidermal growth factor receptor (EGFR)/HER1 is a member of
the HER/erbB family of transmembrane tyrosine kinases. Binding
of specific ligands, such as EGF or transforming growth factor-a,t o
the extracellular domain of EGFR/HER1 results in homodimerisa-
tion or heterodimerisation with another member of the HER/erbB
family, HER2/erbB2, HER3/erbB3 or HER4/erbB4. This dimerisa-
tion induces autophosphorylation of tyrosine residues of the
intracellular domain of EGFR/HER1, which activates intracellular
signalling cascades such as the Ras/Raf/ERK/MAPK, PI-3K/AKT
and PLCg pathways. These interactions modulate several cellular
functions such as proliferative activity and apoptosis. Under
normal conditions, EGFR/HER1 signalling is tightly controlled by
various physiological mechanisms (Yarden and Sliwkowski, 2001).
Aberrant EGFR/HER1 signalling, such as high expression of
EGFR/HER1, is causally associated with enhanced tumour cell
proliferation and shorter survival in patients with solid tumours
such as breast cancer (Arteaga, 2002). It has been reported that
EGFR/HER1 is expressed at high levels in at least 20% of breast
cancers. This high expression has been suggested to correlate with
a shorter survival time and resistance to endocrine therapy in
patients with breast cancer (Sainsbury et al, 1987; Nicholson et al,
1989; Newby et al, 1995). In addition, a series of experimental and
clinical findings have suggested that aberrant activation of tyrosine
receptor kinases, such as EGFR/HER1 and HER2 pathways, play a
causal role in the development of antioestrogen resistance in breast
cancer (van Agthoven et al, 1992; Benz et al, 1993; Houston et al,
1999; Dowsett et al, 2001; Wakeling et al, 2001).
Gefitinib (Iressa, ZD1839) is an orally active EGFR-tyrosine
kinase inhibitor (TKI) that blocks signal transduction pathways
implicated in proliferation and survival of cancer cells (Baselga
and Averbuch, 2000). Recent studies have suggested that gefitinib
induces cell cycle retardation and apoptosis, and inhibits the
growth of several types of human cancer cells expressing EGFR
both in vitro and in vivo (Ciardiello et al, 2000; Sirotnak et al, 2000;
Ciardiello et al, 2001; Moasser et al, 2001; Moulder et al, 2001;
Bianco et al, 2002; Ciardiello et al, 2002; Fujimura et al, 2002;
Huang et al, 2002; Janne et al, 2002; Magne et al, 2002; Williams
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set al, 2002). In addition, human breast cancer cells overexpressing
HER2 or acquiring resistance to the oestrogen receptor (ER)
antagonist, fulvestrant (Faslodex, ICI 182,780), have been reported
to be particularly sensitive to gefitinib (McClelland et al, 2001;
Moulder et al, 2001). Furthermore, phase I trials of gefitinib in
patients with solid tumours refractory to standard chemotherapies
have shown good tolerability and promising antitumour activity
(Baselga et al, 2002; Herbst et al, 2002; Ranson et al, 2002). These
findings suggest that gefitinib will be clinically useful in the
treatment of patients with hormone-refractory breast cancer.
To test the hypothesis that inhibition of the EGFR/HER1
signalling pathway affects the antitumour effect of endocrine
therapy, gefitinib and fulvestrant were administered to human
breast cancer cells. We found that gefitinib increases the
antiproliferative effect of fulvestrant in ER-positive breast cancer
cells under 17b-oestradiol (E2)-supplemented conditions. In
addition, this effect is caused by cell cycle retardation (G1–S
blockade) and an increase in apoptosis. To investigate more
detailed mechanisms of action of gefitinib and fulvestrant, changes
in the expression levels of cyclin-dependent kinase inhibitors
(CDKIs), p21 and p27, an antiapoptotic protein, Bcl-2 and a
proapoptotic protein, Bax, were also investigated.
MATERIALS AND METHODS
Reagents
E2 was purchased from Sigma Chemical Co. (St Louis, MI, USA).
Both fulvestrant and gefitinib were kindly provided by AstraZe-
neca (Macclesfield, UK). E2 and fulvestrant were dissolved with
100% ethanol and added to the medium at a final ethanol
concentration of 0.2%. Gefitinib was dissolved with DMSO and
added to the medium at a final concentration of 0.1%.
Cell lines
KPL-1, KPL-3C and KPL-4 human breast cancer cell lines were
established in our laboratory (Kurebayashi et al, 1995; Kurebaya-
shi et al, 1996; Kurebayashi et al, 1999). KPL-1 cells are derived
from a postmenopausal patient with hormone-refractory breast
cancer. This cell line is ERa-positive and oestrogen responsive in
vitro but not in vivo (Kurebayashi et al, 2000a). KPL-3C cells are
derived from a premenopausal patient with breast cancer
associated with humoral hypercalcemia. This cell line is ERa-
positive and oestrogen responsive both in vitro and in vivo. KPL-4
cells are derived from a postmenopausal patient with inflammatory
skin metastasis from breast cancer. This cell line expresses a high
level of HER2 associated with HER2/neu gene amplification. T47D
and MDA-MB-231 cell lines were kindly provided by Dr Robert B
Dickson (Lombardi Cancer Research Center, Georgetown Uni-
versity Medical Center, Washington DC, USA). All cell lines were
routinely cultured in Dulbecco’s minimal essential medium (D-
MEM) supplemented with 5% fetal bovine serum (FBS).
Expression levels of ER, progesterone receptor (PgR) and
HER family members
The expression levels of ER and PgR in the cell pellets of the breast
cancer cell lines were measured by an enzyme immunoassay using
the ER-EIA and PgR-EIA kits (Dinabot Inc., Tokyo, Japan),
according to the manufacturer’s recommendations. The expression
levels of HER family members were measured by the multiplex
reverse transcription–polymerase chain reaction (RT–PCR) as
described previously (Kunisue et al, 2000; Kurebayashi et al,
2000b). Oligonucleotide primers were designed using a published
sequence of each target gene and synthesised by the solid-phase
triester method. To amplify both the internal control gene (b-
actin) and one of the target genes in a single reaction, multiplex
PCR was carried out. The relative expression levels were calculated
as the density of the product of the respective target genes divided
by that of the control gene. In addition, protein expression levels of
HER1 and HER2 were measured by Western blotting using anti-
HER1 goat polyclonal antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) and anti-HER2 mouse monoclonal antibody
(Santa Cruz Biotechnology), respectively. Detailed procedure of
immunoblot analysis is described below.
Growth assay and cell cycle analysis
To reduce endogenous oestrogen-like activity, phenol red-free
RPMI-1640 medium (Gibco BRL, Bethesda, MD, USA) supple-
mented with 5% dextran-coated charcoal-stripped FBS (Hyclone,
UT, USA) (oestrogen-deprived medium) was used. Approximately
2 10
5 cellswell
 1 were inoculated into 12-well plates (Costar
Corning Inc., Corning, NY, USA) and cultured in D-MEM
supplemented with 5% FBS for 2 days. Then, the cells were
washed twice with phosphate-buffered saline (PBS) and cultured
for 2 days in the oestrogen-deprived medium with vehicle
(control), 1nM E2, the indicated concentrations of gefitinib and/
or fulvestrant. After cell dispersion with 0.05% trypsin (Difco,
Detroit, MI, USA) and 0.02% EDTA in PBS for 10min, the cell
numbers were measured with a Coulter counter (Coulter Electro-
nics Ltd, Harpenden, UK). Triplicate wells were treated in each
experiment.
To investigate the effect of the agents on cell cycle progression, a
part of the harvested cells were stained with propidium iodide
using the CycleTest Plus DNA Reagent kit (Becton Dickinson, San
Jose, CA, USA). Flow cytometry was performed with a FACSCaliber
flow cytometer (Becton Dickinson), and the DNA histogram was
analysed by a CELLQuest version 1.2.2 (Becton Dickinson) as
described previously (Kunisue et al, 2000).
Apoptosis assay
Approximately 5 10
5 cellswell
 1 were plated into T-25 flasks
(Corning Japan, Tokyo, Japan) and cultured in D-MEM supple-
mented with 5% FBS for 2 days. Then, the cells were washed twice
with PBS and cultured for 2 or 4 days in the oestrogen-deprived
medium with vehicle (control), 10mM gefitinib, 1nM E2, 1nM E2
plus 100nM fulvestrant, 1nM E2 plus 10mM gefitinib or 1nM E2
plus 100nM fulvestrant and 10mM gefitinib. Duplicate flasks were
trypsinised and harvested. The percentages of apoptotic cells were
measured with a FACSCaliber flow cytometry (Becton Dickinson)
using an in situ cell death detection kit (Roche Diagnostics GmbH,
Mannheim, Germany), according to the manufacturer’s recom-
mendations as described previously (Kunisue et al, 2000).
Immunoblot analysis
Approximately 4 10
5 cellswell
 1 were plated in six-well plates
(Costar Corning Inc.) and cultured in D-MEM supplemented with
5% FBS for 2 days. Then, the cells were washed twice with PBS and
cultured for 2 days in the oestrogen-deprived medium with vehicle
(control), 10mM gefitinib, 1nM E2, 1nM E2 plus 100nM fulvestrant,
1n M E2 plus 10mM gefitinib or 1nM E2 plus 100nM fulvestrant and
10mM gefitinib. Then, the cells were washed once with cold PBS
and lysed by 200mlwell
 1 of cold RIPA buffer (50mM Tris-HCl
(pH 7.4), 150mM NaCl, 1% Nonidet P-40, 1% deoxycholic acid
sodium, 0.05% SDS) plus 4mlwell
 1 of protease inhibitor (Sigma
Chemical Co.). The cell lysate was clarified by centrifugation at
14000g at 41C for 10min. In total, 20–30mg protein was heated in
Laemmli gel loading buffer for 5min at 951C and subjected to
electrophoresis on 12.5% polyacrylamide gel (Bio-Rad, Richmond,
CA, USA). The protein was transferred to nitrocellulose mem-
branes (Amersham Life Sciences, Buckinghamshire, UK) and
immunoblotted with appropriate primary antibodies. For detec-
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stion, the blots were incubated with the appropriate secondary
antibodies conjugated with horseradish peroxidase (Santa Cruz
Biotechnology), and developed using ECL Plus Western Blotting
Detection Reagents (Amersham Life Sciences), according to the
instructions of the manufacturer. Both anti-p21 and anti-p-27
monoclonal antibodies were obtained from Nippon Becton
Dickinson (Tokyo, Japan). Anti-Bcl-2 and anti-BAX monoclonal
antibodies were obtained from Dako Japan (Tokyo, Japan) and
Medical and Biological Laboratories Co. (Tokyo, Japan), respec-
tively. Both anti-actin and anti-a-tubulin monoclonal antibodies
were obtained from Santa Cruz Biotechnology. Densinometry was
performed using Image-Pro Plus Version 4.0 (Planetron, Tokyo,
Japan). The intensities of the proteins were normalised to the actin
or a-tubulin band and quantified by comparing with those of
control cells. Reproducibility was confirmed in at least two
separate experiments.
Statistical analysis
All values are expressed as the mean7s.e. ANOVA analysis with
StatView computer software (ATMS Co., Tokyo, Japan) was used
to compare the differences between two groups. A two-sided P-
value less than 0.05 was considered to be statistically significant.
RESULTS
Expression levels of ER, PgR and HER family members
KPL-1 and KPL-3C cells expressed a high level of ER and
undetectable PgR in the oestrogen-deprived condition (but PgR
is inducible by an E2 supplementation) (Kurebayashi et al, 1996;
Kurebayashi et al, 2000a). T47D cells expressed a low level of ER
associated with a very high level of PgR in the oestrogen-deprived
condition. Both KPL-4 and MDA-MB-231 cells expressed neither
ER nor PgR (Kurebayashi et al, 2000b; Table 1). In contrast, all cell
lines expressed a detectable level of each HER family member by
the RT–PCR. KPL-4 cells expressed a highest level of HER2, and
MDA-MB-231 expressed a highest level of HER1 (Table 1).
Western blot analysis also supported these findings (Figure 1).
Antitumour effect of gefitinib alone
Gefitinib alone dose dependently inhibited the growth of all breast
cancer cell lines tested (Figure 2). The mean 50%-growth
inhibitory concentrations of gefitinib were 28.571.5mM for KPL-
1 cells, 25.071.0mM for KPL-3C cells, 25.073.0mM for T47 D cells,
10.071.0mM for KPL-4 cells and 10.070.5mM for MDA-MB-231
cells, respectively (n¼2 each). HER1-overexpressing MDA-MB-
231 and HER2-overexpressing KPL-4 cell lines were more sensitive
to gefitinib than the other cell lines.
Effects of E2, fulvestrant and gefitinib on cell growth
In KPL-1, KPL-3C and T47D cells, 1nM E2 significantly stimulated
their growth. Both 100nM fulvestrant and 10mM gefitinib
significantly reduced the growth-stimulatory effect of E2. Simulta-
neous addition of fulvestrant and gefitinib additively reduced the
growth-stimulatory effect of E2. In either KPL-4 or MDA-MB-231
cells, gefitinib significantly inhibited the cell growth but fulvestrant
did not (Figure 3). In contrast, no significant growth inhibitory
effect of fulvestrant was observed in all cell lines tested, and the
simultaneous addition of fulvestrant and gefitinib did not
additively inhibit the growth of the ER-positive cell lines in the
absence of E2 (data not shown).
Table 1 Expression levels of ER, PgR and HER family members in human breast cancer cell lines tested
Cell line ER
a PgR
a HER1
b HER2
b HER3
b HER4
b
KPL-1 79.7713.3 ND
c 1.5 3.0 2.5 1.0
KPL-3C 90.9718.2 ND 0.8 3.0 2.7 1.3
T47D 32.571.0 8480.07720.0 1.3 3.7 2.0 2.2
KPL-4 ND ND 1.8 9.5 2.0 1.1
MDA-MB-231 ND ND 3.0 2.6 0.8 1.1
aFemtomolesmg
 1 protein measured by EIA (mean7s.e.).
bExpression ratio in comparison with internal control (b-actin) by multiplex RT–PCR.
cNot detectable.
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Figure 1 Western blot analysis on expression levels of EGFR/HER1 and
HER2 in five breast cancer cell lines tested. The harvested cells were lysed,
and the lysate was subjected to electrophoresis on polyacrylamide gel. The
protein was transferred to nitrocellulose membranes and immunoblotted
with appropriate primary antibodies. For detection, the blots were
incubated with the appropriate secondary antibodies conjugated with
horseradish peroxidase, and developed using ECL Plus Western Blotting
Detection Reagents. Actin was used as the internal control.
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Figure 2 Effect of gefitinib alone on the cell growth of five human breast
cancer cell lines tested. Semiconfluent cells were cultured for 2 days in the
oestrogen-deprived medium with vehicle, 0.1, 1.0, 10, 20 or 30mM gefitinib.
After cell dispersion, the cell numbers were measured with a Coulter
counter. Triplicate wells were treated in each experiment. Values represent
means7s.e. K — K, KPL-1; K--- K, KPL-3C; , T47D; J--- J, KPL-
4; and J — J, MDA-MB-231.
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sTo clarify the additive antitumour effect of gefitinib and
fulvestrant, various concentrations of gefitinib and fulvestrant
were administered to KPL-3C cells under E2-supplemented
conditions. Either gefitinib or fulvestrant dose dependently
inhibited the growth of KPL-3C cells (Figure 4A). Gefitinib (0.1–
20mM) additively increased the antitumour activity of fulvestrant
(1–200nM) in KPL-3C cells (Figure 4B).
Effects of E2, fulvestrant and gefitinib on cell cycle
progression
In KPL-3C cells, 1nM E2 significantly increased an S-phase fraction
and decreased a G0/G1-phase fraction, that is, stimulated a G1–S
transition. Both 100nM fulvestrant and 10mM gefitinib significantly
inhibited the G1–S transition stimulated by E2, that is, lead to the
G1–S blockade. The simultaneous addition of fulvestrant and
gefitinib additively reduced the upregulation of a G1–S transition
by E2. A slight increase in a sub-G1 fraction was observed in the
cells treated with gefitinib alone. Gefitinib alone significantly
increased the sub-G1 fraction in MDA-MB-231 cells (Table 2).
Effect of gefitinib on apoptosis
To clarify whether the sub-G1 fraction detected by the cell cycle
analysis represented apoptosis, KPL-3C cells treated with E2,
fulvestrant and gefitinib and MDA-MB-231 cells treated gefitinib
alone were subjected to the apoptosis assay. As shown in Figure 5,
a significant increase in the apoptotic fraction was observed in the
treated cells in comparison with the respective control cells.
Effects of E2, fulvestrant and gefitinib on expression levels
of p21, p27, Bcl-2 and Bax
E2 decreased p21 expression in KPL-3C cells (a 21715% reduction
in comparison with control, n¼2). Both fulvestrant and gefitinib
significantly increased the p21 expression decreased by E2 (3078
and 4575% increases, respectively). The simultaneous addition of
the two agents additively increased the p21 expression decreased
by E2 (a 88722% increase). Gefitinib alone also increased p21
expression in comparison with control (a 66728% increase)
(Figure 6A). In contrast, neither E2 nor fulvestrant changed p21
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Figure 3 Effect of E2, fulvestrant and gefitinib on the cell growth of five human breast cancer cell lines tested. Semiconfluent cells were cultured for 2 days
in the oestrogen-deprived medium with vehicle (control, A), 1nM E2 (B), 1nM E2 plus 100nM fulvestrant (C), 1nM E2 plus 10mM gefitinib (D), 1nM E2 plus
100nM fulvestrant and 10mM gefitinib (E) or 10mM gefitinib alone (F). After cell dispersion, the cell numbers were measured with a Coulter counter.
Triplicate wells were treated in each experiment. Values represent means7s.e. *Po0.05 and **Po0.01 in comparison with control.
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Figure 4 Effect of E2, fulvestrant and gefitinib on the cell growth of ER-
positive KPL-3C cells. Semiconfluent cells were cultured for 2 days in the
oestrogen-deprived medium with 1nM E2 plus the indicated concentrations
of gefitinib or ICI 182,780 (A). To clarify additive antitumour effect of
gefitinib and ICI 182,780, semiconfluent cells were cultured for 2 days in the
oestrogen-deprived medium with 1nM E2, 50, 100 or 200nM ICI 182,780
plus the indicated concentrations of gefitinib (B). After cell dispersion, the
cell numbers were measured with a Coulter counter. Triplicate wells were
treated in each experiment. Values represent means7s.e.
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sexpression in MDA-MB-231 cells. Gefitinib alone significantly
increased p21 expression in comparison with control (a 22274%
increase) (Figure 6B). No significant change in p27 expression was
observed in either cell lines treated with these three agents (Figure
6A and B).
E2 significantly increased Bcl-2 expression in KPL-3C cells (a
1967120% increase). Either fulvestrant or gefitinib decreased the
Bcl-2 expression increased by E2 (105733 and 130714%
reductions, respectively). The simultaneous addition of the two
agents additively decreased the Bcl-2 expression increased by E2 (a
169725% reduction). Gefitinib alone did not significantly
decrease Bcl-2 expression (Figure 7A). In contrast, neither E2
nor fulvestrant changed Bcl-2 expression in MDA-MB-231 cells.
Gefitinib alone significantly decreased Bcl-2 expression in
comparison with control (a 46733% reduction) (Figure 7B). No
significant change in BAX expression levels was observed in either
cell lines treated with these three agents (Figure 7A and B).
The relative expression levels of p21 and Bcl-2, which were
normalised to actin or a-tubulin bands, and quantified by
comparing with those of control cells, are shown in Figure 8A
and B.
DISCUSSION
The mechanism of action of the EGFR-TKI gefitinib has been
extensively studied in the last few years. It has been known that
gefitinib selectively inhibits ATP binding to the ATP site of EGFR/
HER1 and this leads to inhibition of ligand-dependent EGFR
autophosphorylation and of transactivation of downstream
signalling pathways, such as Ras/Raf/ERK/MAPK and PI3K/AKT
cascades. Blockade of the EGFR signalling pathways results in not
only retardation of cell cycle progression but also induction of
apoptosis in EGFR-expressing tumour cells. It has been suggested
that the cell cycle retardation is mediated by an increase in the
expression level of a CDKI p27 (Moasser et al, 2001; Albanell et al,
2002; Janne et al, 2002), and that the induction of apoptosis is
mediated by a decrease in the expression level of an antiapoptotic
Table 2 Effects of E2, fulvestrant and gefitinib on cell cycle progression in KPL-3C and MDA-MB-231 cells
Cell line Treatment G0/G1 S G2/M Sub-G1
KPL-3C Control 69.070.1
a 15.570.5 12.770.7 2.970.1
E2 57.770.3** 21.670.4** 18.470.4** 2.370.3
E2+FUL
b 62.970.1** 17.170.1* 15.270.2** 4.870.2**
E2+GEF
c 68.170.1 13.970.1* 14.770.3** 3.270.2
E2+FUL+GEF 80.270.2** 7.970.1** 8.270.2** 3.770.3
GEF 79.571.5** 7.170.8** 7.270.2** 5.770.2**
MDA-MB-231 Control 58.870.8 16.770.3 14.770.3 9.870.2
GEF 49.370.7* 16.570.5 12.670.4* 21.670.6**
aPercentages (mean7s.e.).
bFulvestrant.
cGefitinib. *Po0.05; **Po0.01 in comparison with the respective control.
KPL-3C cells
MDA-MB-231 
cells
Control
Control
E2+gefitinib+fullvestrant
Apoptotic fraction: 11.7 % Apoptotic fraction: 29.0 %
Apoptotic fraction: 11.4 % Apoptotic fraction: 40.0 %
gefitinib
Figure 5 Analyses of apoptosis in KPL-3C and MDA-MB-231 cells treated with E2, fulvestrant and/or gefitinib. Semi-confluent cells were cultured for 4
days in the oestrogen-deprived medium with vehicle (control), 1nM E2 plus 100nM fulvestrant and 10mM gefitinib or 10mM gefitinib alone. The percentages
of apoptotic cells were measured with a flow cytometry using an in situ cell death detection kit. Note the increase in apoptotic cells by the addition of
fulvestrant and gefitinib to E2 in KPL-3C cells and in MDA-MB-231 cells treated with gefitinib alone.
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sprotein Bcl-2 (Bianco et al, 2002; Ciardiello et al, 2002; Nicholson
et al, 2002) or by activation of a proapoptotic protein BAD
(Gilmore et al, 2002). Very recently, it has been reported that the
EGFR-TKI gefitinib increases both p27 and p21 proteins associated
with CDK2–cyclin-E and CDK2–cyclin-A complexes in HER1-
overexpressing head and neck squamous carcinoma cells (Di
Gennaro et al, 2003). In addition, gefitinib has been suggested to
decrease the expression levels of proangiogenic factors, such as
vascular endothelial growth factor and basic fibroblast growth
factor in tumour cells, to inhibit migration and tube formation of
endothelial cells and to reduce the invasive potential of tumour
cells (Ciardiello et al, 2001; Bianco et al, 2002; Fujimura et al, 2002;
Hirata et al, 2002). Synergy of these mechanisms of action of
gefitinib may provide a drastic antitumour effect in vivo.
It has been recognised that activation of oncogenic tyrosine
kinase pathways, such as EGFR signaling pathway, leads to
acquisition of resistance to radiotherapy and cytotoxic chemother-
apy (Skorski, 2002). Actually, several experimental studies have
suggested that the combined treatment with gefitinib and ionising
p21
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Figure 6 Western blot analysis on expression levels of CDKIs p21 and
p27 in KPL-3C (A) and MDA-MB-231 (B) cells. Semi-confluent cells were
cultured for 2 days in the oestrogen-deprived medium with vehicle
(control), 1nM E2, 1nM E2 plus 100nM fulvestrant, 1nM E2 plus 10mM
gefitinib, 1nM E2 plus 100nM fulvestrant and 10mM gefitinib or 10mM
gefitinib alone. The harvested cells were lysed, and the lysate was subjected
to electrophoresis on polyacrylamide gel. The protein was transferred to
nitrocellulose membranes and immunoblotted with appropriate primary
antibodies. For detection, the blots were incubated with the appropriate
secondary antibodies conjugated with horseradish peroxidase, and
developed using ECL Plus Western Blotting Detection Reagents. Actin or
a-tubulin was used as the internal control.
Bax
Bcl-2
Actin
Actin
E2
Fulvestrant
Gefitinib
++++
+++
++
−
−
−
−
−
−
− −
−
E2
Fulvestrant
Gefitinib
++++
+++
++
−
−
−
−
−
−
− −
−
Bax
-Tubulin
Bcl-2
Actin
A
B
Figure 7 Western blot analysis on the expression levels of a pro-
apoptotic protein BAX and an anti-apoptotic protein Bcl-2 in KPL-3C (A)
and MDA-MB-231 (B) cells. Semi-confluent cells were cultured for 2 days
in the oestrogen-deprived medium with vehicle (control), 1nM E2, 1nM E2
plus 100nM fulvestrant, 1nM E2 plus 10mM gefitinib, 1nM E2 plus 100nM
fulvestrant and 10mM gefitinib or 10mM gefitinib alone. The harvested cells
were lysed, and the lysate was subjected to electrophoresis on
polyacrylamide gel. The protein was transferred to nitrocellulose
membranes and immunoblotted with appropriate primary antibodies. For
detection, the blots were incubated with the appropriate secondary
antibodies conjugated with horseradish peroxidase, and developed using
ECL Plus Western Blotting Detection Reagents. Actin or a-tubulin was
used as the internal control.
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sradiation or cytotoxic agents, such as taxanes and cisplatin,
synergistically inhibit the growth of tumour cells both in vitro and
in vivo (Ciardiello et al, 2000; Sirotnak et al, 2000; Ciardiello et al,
2001; Bianco et al, 2002; Ciardiello et al, 2002; Huang et al, 2002;
Magne et al, 2002; Williams et al, 2002). However, no synergistic or
additive activity has been reported with gefitinib and a cytotoxic
agent in phase III clinical trials (Giaccone et al, 2002; Johnson et al,
2002). Furthermore, it has been suggested that high expression of
EGFR or HER2 causes the development of acquired endocrine
resistance in endocrine-responsive breast cancer (Benz et al, 1993;
Houston et al, 1999). Therefore, it might be possible that gefitinib
will enhance the antitumour effect of endocrine agents.
In the present study, gefitinib additively increased the
antitumour effect of the ER antagonist fulvestrant in ER-positive
human breast cancer cells lines tested (Figures 3 and 4B). Cell cycle
and apoptosis analyses revealed that gefitinib and fulvestrant
additively induced a G1–S blockade and apoptosis in these cells
(Table 2 and Figure 5). In addition, Western blot analysis showed
that both agents additively upregulated the expression level of a
CDKI p21 decreased by E2 and additively downregulated the
expression level of an antiapoptotic protein Bcl-2 increased by E2
(Figures 6–8). These findings suggest that the upregulation of p21
expression by these agents may cause the retardation of G1–S
transition, and that the downregulation of Bcl-2 expression may
cause the induction of apoptosis. Unexpectedly, expression levels
of another CDKI p27 did not change during treatment with
gefitinib and fulvestrant (Figure 6). To our knowledge, this is the
first report suggesting that gefitinib upregulates a CDKI p21
expression decreased by E2 and this may induce, at least in part,
the G1–S blockade. In addition, this is also the first report
suggesting that gefitinib downregulates the intrinsic Bcl-2 expres-
sion increased by E2 and this may cause, at least in part, the
induction of apoptosis. However, it is hard to clarify whether these
additive effects, including antitumour activity, induction of G1–S
blockade, induction of p21 expression and decrease in Bcl-2
expression, produced by gefitinib and fulvestrant in ER-positive
breast cancer cells are mediated by the interaction of these drugs
or by the summation of two independent actions.
Gefitinib induced neither a significant G1–S blockade nor
reduction in S-phase fraction in MDA-MB-231 cells. Otherwise, a
significant increase in the p21 expression level was observed
(Figures 6B and 8B). On the other hand, a significant down-
regulation of Bcl-2 and increase in apoptosis was observed at the
same time (Table 2 and Figures 7B and 8B). It might be possible
that a G1–S blockade and reduction in S-phase fraction induced
by gefitinib was drowned by the induction of a massive apoptosis
by gefitinib in the cell cycle analysis or a G1–S blockade appeared
some time before the induction of apoptosis. Further analyses,
such as time course studies of expression levels of CDKIs and
apoptosis-modulating proteins are needed to understand in greater
detail the mechanism of action of gefitinib.
Clinically, combined treatments with endocrine therapy and an
inhibitor of growth factor signalling pathways are thought to be
promising. Rationales of this hypothesis are follows: (1) clinical
studies have suggested that ER-positive breast cancers with a high
expression level of EGFR or HER2 are frequently resistant to
endocrine therapy and have a shorter survival time (Sainsbury et al,
1987; Nicholson et al, 1989; van Agthoven et al, 1992; Newby et al,
1995; Dowsett et al, 2001), (2) artificially increasing expression of
EGFR or HER2 to high levels in ER-positive breast cancer cells leads
to an antioestrogen-resistant phenotype (Benz et al, 1993; Houston
et al, 1999), (3) a prolonged exposure of an antioestrogen to ER-
positive breast cancer cells sometimes results in upregulation of
EGFR or HER2 expression and an antioestrogen-resistant phenotype
(Long et al, 1992; McClelland et al, 2001; Nicholson et al, 2002), (4)
we and others have suggested that an anti-HER2 monoclonal
antibody or inhibitor of HER2 signalling pathway enhances an
antitumour effect of antioestrogens in ER-positive breast cancer
cells with a moderate or high level of HER2 expression (Witters et al,
1997; Kunisue et al, 2000; Kurokawa et al, 2000). Actually,
combination therapy with trastuzumab and an endocrine agent,
the aromatase inhibitor anastrozole, has been tested in a clinical trial
(Winer and Burstein, 2001). Interestingly, it has been reported that a
combined treatment with gefitinib and trastuzumab cooperatively
inhibits the growth of breast cancer cells (Normanno et al, 2002). It
might be an attractive approach to use this combination for the
treatment of antioestrogen-resistant breast cancer.
In conclusion, the present study has suggested that simultaneous
administration of the EGFR-TKI gefitinib and the ER antagonist
fulvestrant may be more efficacious than either agent alone for the
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Figure 8 The relative expression levels of p21 and Bcl-2 in KPL-3C (A)
and MDA-MB-231 (B) cells. Western blot bands were normalized to actin
or a-tubulin bands and quantified by comparing with those of control cells.
Data are shown as the means of two separate experiments; bars, s.e.
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streatment of patients with ER-positive breast cancer, which express
HER1 at various levels. In addition, the additive antitumour effect
of these agents may be mediated by the additive G1–S blockade
mediated by upregulation of p21 and by the additive induction of
apoptosis mediated by downregulation of Bcl-2. These findings
should be clarified in preclinical in vivo studies and in prospective
randomised clinical trials in the near future.
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